QBIO - Q BioMed Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Q BioMed Inc.

366 Madison Avenue
3rd Floor
New York, NY 10017
United States

Full Time Employees1

Key Executives

NameTitlePayExercisedYear Born
Mr. Denis D. CorinChairman, CEO, Pres & CFO240kN/A1973
Mr. William S. RosenstadtGen. Counsel & Director331.26kN/A1968
Mr. David Laskow-PooleyVP of Product Devel.N/AN/A1954
Mr. Robert DerhamVP of Orphan ProductsN/AN/AN/A
Mr. Ari JatwesBus. Devel. AnalystN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a research collaboration with Chemveda Life Sciences India Private Limited for the synthesis of Uttroside B, which is isolated from the leaves of Solanum nigrum and its analogues for use in the clinical trials and treatment of hepatocellular carcinomas, and other targets and therapeutic areas. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was founded in 2013 and is based in New York, New York.

Corporate Governance

Q BioMed Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.